A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2018
At a glance
- Drugs AT 527 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept
- Sponsors Atea Pharmaceuticals
- 09 Nov 2018 Results presented in the Atea pharmaceuticals media release.
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 May 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History